According
to a new market report published by Transparency Market Research " Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share,
Growth, Trends and Forecast 2013 - 2019", the market was valued at USD
11.16 billion in 2012, and is expected to reach USD 15.90 billion by 2019,
growing at a CAGR of 5.2% from 2013 to 2019. Lack of adequate power
infrastructure and increasing demand for reliable electricity delivery are the
major driving forces of this market.
Browse
the full Liver Diseases Therapeutics
Market Report: http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
Liver disease therapeutics market are
increasing aging population inducing chronic diseases such as hepatitis and
liver cancer, increasing global prevalence of liver disorder, high unmet needs
existing in liver cancer and increased vaccination in emerging economies.
However side-effects and risks associated with the medication, strict FDA
approval norms and other government regulations and availability of alternate
treatment procedures may act as the barrier for this market. Strong pipeline
drugs and consolidation opportunities in the healthcare industry will pose future
growth prospect for this market.
Anti-viral
drugs represent the largest market in the liver disease therapeutics, which is
justified by the fact that many oral, direct-acting antiviral medications are
in development phase for treating hepatitis C. Currently, anti-virals are only
available for hepatitis B and C. However, many anti-viral hepatitis C pipeline
drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir
(NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease
Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate
this market in near future.
The
major players in the liver diseases therapeutics market include Astellas Pharma
Inc, Gilead Science Inc, Merck & Co., Bristol-Myers Squibb, Novartis,
Pfizer and Roche. In 2011, Astellas was the market leader in the
immunosuppressants drugs market for liver diseases followed by Pfizer. In liver
disease vaccines market, GlaxoSmithKline Pharmaceuticals Limited (GSK)
represented as the major market player with a share of 45% in 2011. Bristol Myers
Squibb had the largest market share in anti-viral drugs market for liver
diseases followed by Gilead science in 2011.
This
research is specially designed to estimate and analyze the demand for liver
diseases therapeutics in global market. The research provides an in-depth
analysis of the product sales, drugs class wise trend analysis and the major
player pertaining to this market. High level analysis of the mentioned drug
class of global liver diseases therapeutics market is performed and the report
provides detailed analysis, comprehensive historical data and statistically
tested forecast of the drug classes thus covered. Detailed qualitative
information is given for different liver diseases and the application of
different drugs as the treatment and therapy option.
About us:
Transparency Market Research is a market intelligence company providing
global business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking insight
for thousands of decision makers.
We are privileged with highly experienced team of Analysts, Researchers
and Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information. Our business offerings represent
the latest and the most reliable information indispensable for businesses to
sustain a competitive edge.
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
No comments:
Post a Comment